A study of A197 in Subjects With Dry Eye Disease

The company Aramis Biosciences, Inc is enrolling patients into the clinical trial investigating A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease.

The objectives of this trial are to assess the safety, tolerability and efficacy of A197 ophthalmic solution in comparison to a vehicle control in the treatment of subjects with Dry Eye Disease.

The study start date is January 25, 2022.

This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT05238597.

Clinical Research News

Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products
Submission of comments on ICH E6 (R3) Guideline for Good Clinical Practice(GCP) - Step 2b 
ICH E6(R3) Good Clinical Practice guidance - Step 2 Public Consultation
The study of the new investigational drug for acute myeloid leukemia and myelodysplastic syndrome
Open Label study of entrectinib in ROS1 gene fusion-positive rare adult, paediatric and teenage/young adult cancers
Gasherbrum Bio, Inc is starting the study of GSBR-1290 drug in overweight or obese healthy adults
A new study of Dexpramipexole in adolescents and adults with severe Eosinophilic Asthma

Prossimi studi clinici

A study of A197 in Subjects With Dry Eye Disease

All jobs

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi